- Home
- DARE
DARE
Dare Bioscience Inc.
as 05-30-2025 4:00pm EST
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $12.50 | AVG Volume (30 days): | 18.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.67 - $6.24 | Next Earning Date: | 05-13-2025 |
| Revenue: | $25,909 | Revenue Growth: | -99.08% |
| Revenue Growth (this year): | 11398.36% | Revenue Growth (next year): | 1808.62% |
Latest Dare Bioscience Inc. News
DARE Breaking Stock News: Dive into DARE Ticker-Specific Updates for Smart Investing
Thomson Reuters StreetEvents
17 days ago
Q1 2025 Dare Bioscience Inc Earnings Call
GuruFocus.com
18 days ago
Dare Bioscience Inc (DARE) Q1 2025 Earnings Call Highlights: Strategic Expansions and Cost ...
Zacks
18 days ago
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates
GlobeNewswire
18 days ago
Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update
GlobeNewswire
25 days ago
Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025
GlobeNewswire
a month ago
Daré Bioscience to Present at the Fierce Pharma Engage Summit on Breaking Barriers and Building Access: Communicating Bold Moves in Women’s Health Innovation
GlobeNewswire
2 months ago
Daré Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year
Thomson Reuters StreetEvents
2 months ago
Q4 2024 Dare Bioscience Inc Earnings Call
Compare DARE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DARE Dare Bioscience Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.